Next 10 |
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral inve...
Merger activity increased significantly last week with ten new deals announced. The merger of WPX Energy (WPX) and Devon Energy Corporation (DVN). Morgan Stanley (MS) completes the acquisition of E*TRADE Financial Corporation (ETFC). For further details see: Me...
Merger activity increased last week with one new deal announced. The acquisition of Standard AVB Financial by Dollar Mutual Bancorp. InnerWorkings receives shareholder approval. For further details see: Merger Arbitrage Mondays - A Very Active Quarter Draws To A Clo...
NEW YORK, NY / ACCESSWIRE / September 19, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Maxim Integrated Products, Inc. (NASDAQ: MXIM...
Principia Biopharma (NASDAQ: PRNB ) has dosed the first patient in an open label two-arm Phase 2A trial, evaluating rilzabrutinib in IgG4-related disease (RD), an immune-mediated fibroinflammatory condition that is capable of affecting multiple organs. More news on: Principia Biop...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to e...
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Principia Biopharma Inc. (NASDAQ:PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sa...
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Juan Monteverde , founder, and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Pfenex Inc. (NYSE American: PFNX ) relating to it...
SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Martin Babler, ...
NEW YORK , Sept. 10, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Principia Biopharma Inc. (NASDAQ: PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties r...
News, Short Squeeze, Breakout and More Instantly...
Principia Biopharma Inc. Company Name:
PRNB Stock Symbol:
NASDAQ Market:
Principia Biopharma Inc. Website:
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral inve...
NEW YORK, NY / ACCESSWIRE / September 19, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Maxim Integrated Products, Inc. (NASDAQ: MXIM...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to e...